Drug Profile
Sibenadet
Alternative Names: AR-C68397; AR-C68397AA; ARL 68397; C 68397; FPL 68397; Viozan™Latest Information Update: 28 Jun 2001
Price :
$50
*
At a glance
- Originator AstraZeneca R&D Charnwood
- Developer AstraZeneca Pharmaceuticals; AstraZeneca R&D Charnwood
- Class Small molecules; Thiazoles
- Mechanism of Action Beta 2 adrenergic receptor agonists; Dopamine D2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 28 Jun 2001 Discontinued-I for Asthma in United Kingdom (Inhalation)
- 28 Jun 2001 Discontinued-III for Chronic obstructive pulmonary disease in Europe (Inhalation)
- 28 Jun 2001 Discontinued-III for Chronic obstructive pulmonary disease in USA (Inhalation)